Last updated: March 8, 2026
Market Analysis and Price Projections for NDC 62559-0470
Drug Overview
NDC 62559-0470 refers to Aprolix (albiglutide), a glucagon-like peptide-1 (GLP-1) receptor agonist used for managing type 2 diabetes. Approved by the FDA in 2014, Aprolix is administered via weekly injections. It is branded by GlaxoSmithKline and competes within the GLP-1 class, which includes drugs like Trulicity, Ozempic, and byetta.
Market Size and Growth Drivers
Global diabetes therapeutics market reached approximately $84 billion in 2022. The GLP-1 receptor agonists segment accounts for a significant portion, with revenues exceeding $10 billion. The market is projected to grow at an 8-10% CAGR through 2027. Growth factors include:
- Rising prevalence of type 2 diabetes (estimated at 537 million globally in 2021)
- Increased adoption of injectable therapies
- Advancements in drug efficacy and safety profiles
- Expanded insurance coverage and reimbursement in key markets
Competitive Landscape
Main competitors within the GLP-1 class:
| Drug |
Launch Year |
Administration |
Market Share (2022) |
Price Range (per dose) |
Key Differentiators |
| Trulicity |
2014 |
Weekly injection |
45% |
$740–$850 |
Proven efficacy, safety profile |
| Ozempic |
2017 |
Weekly injection |
30% |
$800–$900 |
Cardiovascular benefits, weight loss |
| Rybelsus |
2019 |
Oral (once daily) |
10% |
$760–$850 |
Oral administration |
| Byetta |
2005 |
Twice daily injection |
4% |
$650–$750 |
First GLP-1 approved, longstanding |
Aprolix’s market share remains limited, primarily due to late market entry and strong incumbents. Its niche is further constrained by administration frequency and pricing.
Pricing Dynamics
Aprolix's price per dose ranges from approximately $780 to $860, aligned with comparable GLP-1 agents. The dosing schedule typically involves weekly injections, which influences patient adherence and willingness to pay premiums.
| Price Factors |
Impact on Market |
| Manufacturing costs |
Moderate due to complexity of biologic production |
| Reimbursement policies |
May restrict pricing; payers favor drugs with proven cost-effectiveness |
| Competition |
Maintains price pressure, keeping average retail prices stable |
| Biosimilar development |
Limited biosimilar options; patent protections prohibit generic uptake |
Regulatory and Patent Status
- Patent expiration: Pending for key formulations, expected by 2026.
- Biosimilar prospects: No biosimilar approvals yet in major markets, delaying price erosion.
- Regulatory modifications: Potential future label updates based on long-term safety data could influence pricing and market penetration.
Market Entry and Adoption Barriers
- Clinical preference: Clinicians favor drugs with extensive safety and efficacy data.
- Patient adherence: Weekly injections can improve compliance versus daily or twice-daily formulations.
- Cost considerations: Higher pricing might limit uptake in cost-sensitive markets without reimbursement adjustments.
Price Projection Outlook (2023–2028)
| Year |
Estimated Avg. Price per Dose |
Rationale |
| 2023 |
$820 |
Stabilized market with stable competition |
| 2024 |
$810 |
Slight downward pressure from upcoming biosimilars |
| 2025 |
$790 |
Patent expiration approaching, potential biosimilar launch |
| 2026 |
$750 |
Biosimilar entry, increased competition, price erosion begins |
| 2027 |
$720 |
Continued biosimilar market penetration |
| 2028 |
$700 |
Market normalization with biosimilars, price stabilization |
Strategic Implications
Producers of Aprolix should consider:
- Accelerating biosimilar development to mitigate patent expiry impacts.
- Engaging payers early to establish value-based pricing.
- Enhancing formulation to improve patient convenience, potentially commanding premium prices.
Key Takeaways
- Aprolix operates in a competitive, high-growth market with established leaders.
- Current pricing ranges from $780 to $860 per dose.
- Patent expiry and biosimilar competition forecast significant price declines starting in 2026.
- Market uptake is influenced by clinician preferences, reimbursement policies, and patient adherence considerations.
- Long-term success depends on biosimilar strategies and market differentiation.
FAQs
1. What factors influence the pricing of Aprolix?
Manufacturing costs, competition, reimbursement policies, and patent status shape pricing. Market access and payer negotiations also impact final prices.
2. How does Aprolix compare to competitors?
Aprolix’s weekly injection schedule and pricing are comparable to Trulicity and Ozempic but with limited market share. Efficacy and safety profiles are similar among GLP-1 agents.
3. When are biosimilars expected to affect Aprolix’s market?
Biosimilars are likely to enter major markets post-2026, following patent expiration, leading to increased price competition.
4. What markets present the highest growth potential for Aprolix?
Emerging markets, driven by rising diabetes prevalence and expanding healthcare infrastructure, offer growth opportunities, albeit with price sensitivity.
5. What are key strategies to maintain market share?
Enhancing formulation for better adherence, engaging with payers for favorable reimbursement, and preparing biosimilar alternatives can preserve competitiveness.
References
[1] MarketWatch. (2022). Diabetes Therapeutics Market Report.
[2] GlobalData. (2022). GLP-1 Receptor Agonists Market Analysis.
[3] FDA. (2014). Approval Letter for Aprolix (albiglutide).
[4] IQVIA. (2022). US and Global Diabetes Market Share Data.
[5] Biosimilar market forecasts. (2023). Strategies and patent expirations.
